KPTI - Karyopharm Therapeutics reports Q4 earnings miss; initiates FY23 outlook

• Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q4 GAAP EPS of -$0.43 misses by $0.09 .
• Revenue of $33.6M (-73.4% Y/Y) misses by $0.14M .
• Cash, cash equivalents, restricted cash and investments as of December 31, 2022 totaled $279.7 million, compared to $235.6 million as of December 31, 2021.
• 2023 Financial Outlook : Based on its current operating plans, Karyopharm expects the following for full year 2023: Total revenue to be in the range of $160 million to $175 million vs $162.24M consensus. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from our partners.
• U.S XPOVIO net product revenue to be in the range of $125 million to $140 million.
• Non-GAAP R&D and SG&A expenses, which exclude stock-based compensation expense, to be in the range of $260 million to $280 million.
• The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2025.

For further details see: